Beyond the Bloat: Addressing the Neuropsychiatric Burden of Retrograde Cricopharyngeus Dysfunction through Targeted Botulinum Toxin Intervention

Highlights

• Retrograde Cricopharyngeus Dysfunction (RCPD) is associated with a disproportionately high prevalence of comorbid anxiety (73%) and depression (68%).
• Cricopharyngeal botulinum toxin injection (CPBTI) provides more than just physiological relief, resulting in statistically significant reductions in GAD-7 and PHQ-9 scores.
• Improvements in mental health outcomes are sustained up to 6 months post-injection, suggesting that the psychological burden is largely secondary to the chronic physical symptoms of the condition.
• Clinicians should screen RCPD patients for mental health comorbidities as part of a holistic, multidisciplinary treatment approach.

Background

Retrograde Cricopharyngeus Dysfunction (RCPD), colloquially known as “no-burp syndrome,” is a clinical entity first formally characterized by Bastian et al. in 2019. It is defined by the inability of the cricopharyngeus muscle—the primary component of the upper esophageal sphincter (UES)—to relax in a retrograde fashion to allow the venting of gas from the esophagus. The resulting clinical tetrad includes an inability to belch, audible “gurgling” noises from the neck and chest (borborygmi), severe abdominal bloating/distension, and excessive flatulence.

While the physiological mechanisms of RCPD are increasingly understood as a failure of myogenic relaxation or a lack of coordination during the belch reflex, the secondary impact on patient quality of life and psychological well-being has remained under-researched. For many patients, the chronic abdominal pain and the social embarrassment caused by involuntary gurgling and flatulence lead to significant lifestyle modifications, social withdrawal, and psychological distress. Until recently, the psychiatric dimensions of this dysfunction were largely anecdotal. The study by Simko and Tritter (2026) provides a critical, evidence-based look at the neuropsychiatric burden of RCPD and the transformative power of targeted chemodenervation.

Key Content

The Prevalence of Mental Health Comorbidities in RCPD

Epidemiological data from the recent longitudinal study indicates that RCPD is not merely a localized functional disorder but one with systemic psychological implications. Among a cohort of 77 patients seeking treatment, 61% self-reported a diagnosed mental health comorbidity (MHC) prior to intervention. This rate significantly exceeds the general population prevalence for anxiety and depressive disorders, suggesting a strong correlation between the chronicity of RCPD symptoms and psychiatric distress.

Validated screening tools used in the study revealed the following baseline statistics:

• Anxiety (GAD-7): 73% of patients exhibited at least mild anxiety.
• Depression (PHQ-9): 68% of patients exhibited at least mild depression.
• Autonomic Symptom Questionnaire (ASQ): Baseline mean scores were elevated (112.4), reflecting high systemic symptom burden.

Therapeutic Intervention: Cricopharyngeal Botulinum Toxin Injection (CPBTI)

The gold standard for RCPD treatment is the injection of Botulinum Toxin Type A (BoNT-A) into the cricopharyngeus muscle. This procedure effectively induces a temporary paresis of the muscle, lowering the threshold for retrograde gas passage. While the pharmacological effect of the toxin typically wears off within 3 to 4 months, the majority of patients experience a permanent “reset” of the belch reflex.

Simko and Tritter (2026) utilized a longitudinal design to track patients at 6 weeks and 6 months post-CPBTI. The procedural success in restoring the ability to belch was accompanied by a rapid and significant decline in psychiatric scores. The mean GAD-7 (anxiety) score dropped from 8.16 (pretreatment) to 5.04 at 6 weeks and further to 4.4 at 6 months (p < 0.001). Similarly, PHQ-9 (depression) scores decreased from 7.87 to 4.20 over the same period (p = 0.002).

Statistical Significance and Clinical Improvement (MCID)

To ensure that the observed changes in scores were not just statistically significant but also clinically meaningful, the researchers utilized Minimal Clinically Important Difference (MCID) values. The results were striking:

• 64% of patients reached the MCID for GAD-7, indicating a substantial reduction in anxiety that meaningfully impacted their daily lives.
• 60% of patients reached the MCID for PHQ-9, demonstrating a significant alleviation of depressive symptoms.

The sustained nature of these improvements at the 6-month mark—at which point the botulinum toxin has likely been metabolized—supports the hypothesis that the resolution of physical dysfunction leads to a secondary resolution of psychological distress.

Expert Commentary

The findings of Simko and Tritter underscore a critical paradigm in functional disorders: the “Gut-Brain-Throat Axis.” Patients with RCPD often spend years, if not decades, being misdiagnosed with irritable bowel syndrome (IBS), acid reflux, or generic anxiety disorders. The constant physical pressure of trapped gas, combined with the lack of medical validation, creates a fertile ground for chronic anxiety.

From a mechanistic standpoint, CPBTI works by reducing the hypertonicity of the cricopharyngeus. The psychological relief likely stems from two factors: first, the immediate cessation of physical pain and bloating; and second, the elimination of social anxiety related to involuntary borborygmi and flatulence. The fact that mental health improvements persist beyond the duration of the toxin suggests that once the physiological “gate” is opened, the patient’s neurological state stabilizes.

However, clinicians must remain cautious. While CPBTI is highly effective, approximately 35-40% of patients in this study did not meet the MCID for mental health improvement despite physical symptom relief. This suggests that in a subset of the RCPD population, anxiety and depression may be primary conditions or have become independent of the physical dysfunction. Therefore, CPBTI should be viewed as a vital component of a broader treatment plan that may still require traditional psychiatric support.

Conclusion

RCPD is a significant contributor to mental health morbidity in affected individuals. The high prevalence of anxiety and depression among these patients is not a primary psychiatric failure but a secondary consequence of a debilitating functional upper airway/esophageal disorder. The efficacy of CPBTI in reducing these symptoms is robust and sustained, providing a compelling argument for the early diagnosis and treatment of RCPD.

Future research should focus on the long-term (multi-year) psychiatric outcomes of CPBTI and explore whether early intervention in pediatric or adolescent populations can prevent the development of these mental health comorbidities. For now, the evidence is clear: treating the muscle can help heal the mind.

References

• Simko AP, Tritter AG. The Mental Health Impact of Retrograde Cricopharyngeus Dysfunction (RCPD) and Its Treatment. The Laryngoscope. 2026-03-11. PMID: 41810519.
• Bastian RW, Smithson ML. Inability to Belch and Associated Symptoms Due to Retrograde Cricopharyngeus Dysfunction: Diagnosis and Treatment. Oto Open. 2019;3(1). PMID: 31236539.